Korean J Urol Oncol.  2020 Apr;18(1):11-17. 10.22465/kjuo.2020.18.1.11.

The Current Status of Metastatic Castration-Naïve Prostate Cancer Management

• Choi SM
• Choi JH
• Hwa JS

• KMID: 2502095
• DOI: http://doi.org/10.22465/kjuo.2020.18.1.11

Abstract

During last many decades, androgen deprivation therapy (ADT) was the main treatment of choice for metastatic castration-naïve prostate cancer (mCNPC). However, there are now more possible treatment options for mCNPC. In CHAARTED, GETUG-AFU 15, and STAMPEDE trial, docetaxel added to ADT improved overall survival compared to ADT alone in mCNPC. Also, STAMPEDE and LATITUDE trial revealed that abiraterone added to ADT improved overall survival compared to ADT alone for mCNPC patient. Furthermore, ARCHES and ENZAMET trial showed that enzalutamide added to ADT also can be a treatment option for mCNPC. Apalutamide added to ADT also improved survival compared to ADT alone in castration resistant prostate cancer patient. The usefulness of radiation therapy to primary tumor in mCNPC has also been studied in HORRAD and STAMPEDE trial. There are many ongoing trials for mCNPC setting. The aim of this paper is to review the current status of mCNPC management options. (Korean J Urol Oncol 2020;18:11-17)

Keyword

Metastatic castration-nave prostate cancer; Docetaxel; Abiraterone; Enzalutamide; Apalutamide; Radiation therapy